Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2019 August;71(4):263-71 > Minerva Ginecologica 2019 August;71(4):329-43



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Ginecologica 2019 August;71(4):329-43

DOI: 10.23736/S0026-4784.18.04293-4


language: English

Circulating visfatin levels in the second and third trimester of pregnancies with gestational diabetes: a systematic review

Nikolai P. PACE 1 , Antonia BONELLO 1, Mohsin H. ROSHAN 1, Josanne VASSALLO 2

1 Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta; 2 Department of Medicine, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

INTRODUCTION: There are multiple published conflicting associations of the adipocytokine visfatin with gestational diabetes. In this study, we attempted to investigate this relationship via a systematic review of the published literature.
EVIDENCE ACQUISITION: Literature retrieval using PubMed, Google Scholar, Scopus and Hydi databases followed by article selection and data extraction were conducted. Relevant studies published up to June 2018 were included. In total, 29 cohorts that were published in 27 articles were analyzed. Three studies carried out in early pregnancy were excluded. A total of 2365 individuals, with 1069 gestational diabetes (GDM) cases and 1296 controls from studies describing visfatin in the second or third trimester of gestation were included.
EVIDENCE SYNTHESIS: The difference in visfatin levels between women with GDM and the controls in the second and third trimester was measured by weighted mean difference (WMD) and 95% confidence intervals (CI). Heterogeneity was inspected by using both subgroup and meta-regression analysis. Analysis was restricted to studies describing singleton pregnancies. The quality of included studies was assessed by the Newcastle-Ottawa Scale.
CONCLUSIONS: No significant difference in circulating visfatin levels in GDM during the second trimester of pregnancy (WMD -0.30 ng/mL, 95% CI: -2.06, 1.45, SE=0.895, P=0.733) was detected. Meta-analysis of the studies in the third trimester revealed a significant negative effect, that was however driven by only one study. This finding limits the meaningful interpretation of the pooled analysis. Significant heterogeneity was identified between studies, and meta-regression analysis showed that homeostatic model assessment for insulin resistance contributes significantly to heterogeneity. In conclusion, our findings suggest that peripheral blood visfatin concentration cannot be robustly associated with gestational diabetes status in the second and third trimesters of pregnancy.

KEY WORDS: Nicotinamide phosphoribosyltransferase; Diabetes, gestational; Insulin resistance; Adipokines

top of page